Loading...
•
Sep 30, 2024
Day One Q3 2024 Earnings Report
Reported a net income of $37.0 million and OJEMDA net product revenues of $20.1 million.
Key Takeaways
Day One Biopharmaceuticals, Inc. announced its third quarter 2024 financial results, featuring $20.1 million in OJEMDA net product revenue and $73.7 million in license revenue. The company ended the quarter with $558.4 million in cash, cash equivalents and short-term investments.
OJEMDA net product revenues were $20.1 million for the third quarter of 2024.
License revenue from the sale of ex-U.S. commercial rights for tovorafenib was $73.7 million for the third quarter of 2024.
Net income totaled $37.0 million for the third quarter of 2024.
Cash, cash equivalents and short-term investments totaled $558.4 million as of September 30, 2024.
Revenue by Segment
Forward Guidance
The company plans to continue to drive growth by advancing programs and pipeline, including DAY301, a potential first-in-class ADC targeting PTK7 expected to be in the clinic in the coming months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...